**Supplementary Table S1.** Characteristics of the*Apcfl/fl KrasG12D/+(A2K1P0)*, *Apcfl/fl Pik3cap110\* (A2K0P1)*, and *Apcfl/fl KrasG12D/+ Pik3cap110\* (A2K1P1)* mice treated with Adeno-Cre at 40-50 days of age per the protocol described in Materials and Methods. These mice are able to live up to ~11 months post Adeno-Cre treatment, allowing sufficient time for investigations into tumorigenesis and therapeutics.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Genotype** | **N of mice** | **Percent of mice that developed tumors** | **Time (weeks) to tumor identification,  mean (range)** | **N of tumors per mouse, mean (range)** | **Survival time (days) post Adeno-Cre treatment, mean (range)** |
| A2K1P1 | 9 | 78% | 4 (3-8) | 3 (1-8) | 244 (59-303) |
| A2K1P0 | 5 | 80% | 5 (2-7) | 2 (1-2) | 200 (180-240) |
| A2K0P1 | 25 | 80% | 6 (3-10) | 1 (1-2) | 294 (91-321) |